A cohort of patients responsive to treatment with ranibizumab but resistant to~aflibercept were identified in a previously conducted retrospective study. Identified~patients will have their blood drawn for genome wide sequencing. The sequencing~data will be compiled and analyzed in an attempt to identify a common genetic basis~for patients susceptible to ranibizumab but resistant to aflibercept.~Blood samples will be drawn for genetic analysis for all patients enrolled in the study.~The sample (1 tube- 6mL of blood) will be collected using - 8.5mL PAXgene Blood DNA~Tubes (http://www.qiagen.com/products/catalog/sample-technologies/dna-sample-~technologies/genomic-dna/paxgene-blood-dna-tubes).~Samples will be stored at -80 until time for analysis. Note that some blood draws will be performed at~satellite clinics and transported to main facility for storage in -80 freezer. It is the understanding of~ARC PI and staff that the PAXgene Blood DNA Tubes keep samples stable at room temp for 1-2~days.~However, staff will transport samples in timely fashion (room temp, on ice, dry ice,~etc), to -80 freezer for storage until all samples are collected. Once all samples are~collected, they will be shipped to Genentech for analysis. DNA extraction, the generation of genetic~data, and subsequent analysis will be performed at Genentech or via third party. DNA will be assayed~for polymorphisms through genome wide SNP chip or whole genome sequencing. The subject's~genotype or haplotype will be correlated with their visual response and OCT response.
A cohort of patients responsive to treatment with ranibizumab but resistant to~aflibercept were identified in a previously conducted retrospective study. Identified~patients will have their blood drawn for genome wide sequencing. The sequencing~data will be compiled and analyzed in an attempt to identify a common genetic basis~for patients susceptible to ranibizumab but resistant to aflibercept.